Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis

Davies, Laura, Shehadeh, Rasheed, Watkins, W. John ORCID: https://orcid.org/0000-0003-3262-6588, Jolles, Stephen, Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909 and Tallantyre, Emma C. ORCID: https://orcid.org/0000-0002-3760-6634 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 , 415. 10.1007/s00415-025-13133-w

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Abstract Background: Anti-CD20 monoclonal antibodies are now a common first-line treatment for multiple sclerosis (MS). Rituximab, ocrelizumab, and ofatumumab have all been associated with a dose-dependent risk of hypogammaglobulinaemia, but its relevance in clinical practice remains uncertain. Objectives: To study infection rates over time in a real-world cohort of people treated with ocrelizumab for MS, and their relationship to serum immunoglobulin. Design: Observational study of 152 people receiving ocrelizumab for MS followed for up to 5.6 years (mean 2.7 years). Results: Mean (SD) annualized changes in immunoglobulins during ocrelizumab treatment were IgM −0.22 g/L/year (0.4), IgG −0.38 g/L/year (0.9), IgA −0.03 g/L/year. Rates of self-reported infection increased significantly during the first 4 years of treatment. Infection rates were not only associated with total immunoglobulin levels but also independently associated with age, comorbidity, and female sex. We demonstrated for the first time that 29 out of 34 (87%) people on ocrelizumab with IgG in the lower normal range had sub-protective antibody responses to pneumococcus/haemophilus influenzae. Conclusions: Real-world observational studies complement open-label extensions of clinical trials, often by having a more representative cohort and more complete follow-up. Our data suggest that while serious infections are rare in people on ocrelizumab, non-serious infections become increasingly burdensome. We offer practical suggestions on mitigating the risk of infection on ocrelizumab and other anti-CD20 medications.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Schools > Medicine
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	23 May 2025
Date of Acceptance:	1 May 2025
Last Modified:	23 May 2025 13:45
URI:	https://orca.cardiff.ac.uk/id/eprint/178415

Actions (repository staff only)

Edit Item